You are here: Industry Insights > HCC

News List

Against Liver Cancer, Statins Helps Novel Liver Cancer Drug Development Yuntian/PharmaSources
April 20, 2023
Statins help to improve liver cancer and have been confirmed by a large number of clinical and scientific trials.
Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003 prnasia
January 05, 2022
Harbour BioMed ("HBM", HKEX: 02142) announced that, its next generation anti-CTLA-4 fully human heavy-chain only antibody (HCAb), HBM4003, has completed the first dosing of first patient...
A target for potential cancer drugs may, in fact, worsen disease WorldPharmaNews
November 11, 2021
In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyrosine phosphatase 2 or more briefly, Shp2.
FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer AmericanPharmaceuticalReview
November 10, 2021
Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced that an Investigational New Drug application (IND) for a trial of PXS-5505 in hepatocellular carcinoma (HCC)...
Lion TCR Announces FDA IND Clearance for its LioCyx-M004 for Hepatocellular Carcinoma prnasia
September 28, 2021
Lion TCR Pte Ltd, a clinical-stage biotech company specialized in T Cell Receptor (TCR) T cell therapy today announced that it has received clearance from U.S. Food...
Innovent Announces the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with BYVASDA® (bevacizumab biosimilar injection) as First-Line Therapy for People with Hepatocellular Carcino prnasia
June 28, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases today announced that the ...
Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305 for the First-Line Treatment of Hepatocellular Carcinoma Published in The Lancet Oncology prnasia
June 21, 2021
Innovent Biologics, Inc. today announced that data from the ORIENT-32 study have been published in The Lancet Oncology.
OriginCell Therapeutics Presents Positive Results of GPC3 CAR-T in HCC Trial at the 2021 ASCO Annual Meeting prnasia
June 07, 2021
On June 4, 2021 (EST), OriginCell Therapeutics (Shanghai) Co., Ltd., together with Lishui Central Hospital affiliated to Zhejiang University and Shanghai Changzheng Hospital, presented the updated data from the on-going trial of Ori-CAR-001 ...
Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody prnasia
May 12, 2021
Harbour BioMed announced the dosing of the first patient in its part 2 of phase I (phase Ib/IIa) clinical study of its next-generation anti-CTLA-4 antibody, where Australian patients with metastatic or advanced melanoma, hepatocellular carcinoma (HCC) ...
Immuno-oncology to be a dominant class of drugs for hepatocellular carcinoma by 2029: GlobalData expresspharma
April 23, 2021
Class-wide sales of IO are expected to grow to 72.2 per cent of the market, contributing $3.8 billion to global sales in 2029 and growing at a CAGR of 28 per cent.

Previous page 1 2 3 4 Next page